The research centered on 129 individuals diagnosed with OCD, utilizing robust psychometric instruments such as the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) for assessing symptom severity, the Resilience Scale for Adults (RSA) to quantify various facets of psychological resilience, and the TEMPS-A questionnaire to categorize temperamental dominance. By integrating these tools, the study sought to delineate whether those exhibiting DDT manifest distinct patterns in resilience that correlate with their OCD symptomatology.

A critical aspect of the methodology involved stratifying patients based on depressive temperament using both validated cutoff scores and standardized z-scores derived from the depressive subscale of the TEMPS-A. Complementing this, participants’ depressive and anxiety symptoms were quantified through the Beck Depression Inventory (BDI) and Beck Anxiety Inventory (BAI), ensuring that mood state confounders were thoroughly characterized.

Results revealed that individuals with a dominant depressive temperament experienced markedly higher levels of depression and anxiety, in parallel to increased obsession severity as measured by the Y-BOCS. These findings underscore a phenotype of OCD that is intensely burdened not only by obsessive-compulsive pathology but also by affective dysregulation inherent in depressive temperament.

Interestingly, the resilience profiles of patients with DDT diverged significantly from those without this temperament. Subscales encompassing perception of future, structured style, social competence, family cohesion, and social resources were notably diminished in the DDT group, suggesting a pervasive erosion of psychological resilience dimensions critical for adaptive functioning. The exception was the perception of self, which remained comparatively unaltered, hinting at a complex modulation of self-concept in this subgroup.

Paradoxically, certain resilience components such as structured style—reflective of organizational skills and planning ability—were observed to be higher relative to other resilience metrics despite greater clinical severity. This phenomenon may point to compensatory cognitive strategies or rigidity in behavior often seen in OCD, especially when filtered through the lens of depressive temperament.

Delving deeper, partial correlation analyses, which controlled for confounding depressive symptoms, clarified that within the DDT subgroup, more intense obsessive-compulsive manifestations were tightly linked to weakened resilience resources, most notably family cohesion. This association eloquently highlights the potential role of interpersonal and environmental factors in modulating OCD severity within affective temperament contexts.

These nuanced findings challenge the reductionist view of OCD as a purely anxiety-driven disorder and spotlights the layered influence of temperament and resilience. The presence of DDT appears to amplify emotional vulnerability and degrade resilience capacities, thereby potentiating symptom severity. Such insights impart a critical dimension to psychiatric assessments, advocating for comprehensive evaluations encompassing temperament profiling and resilience metrics.

From a clinical perspective, this research advocates for tailored interventions that transcend symptom alleviation to address underlying affective vulnerabilities and fortify resilience. Therapeutic modalities aimed at enhancing family cohesion and bolstering social resources may offer substantive benefit for patients exhibiting DDT alongside OCD symptoms.

Moreover, the observed resilience deficits and the paradoxical strength in structured style within the DDT cohort offer intriguing avenues for cognitive-behavioral strategies that leverage preserved organizational skills to scaffold resilience-building programs. This approach aligns with contemporary personalized medicine paradigms seeking to harmonize treatment with individual temperament and psychosocial profiles.

Importantly, the study delineates the enduring relevance of temperament-resilience interplay in OCD independent of depressive symptomatology, reinforcing the notion that emotional and cognitive substrates interplay dynamically rather than in isolation. Such paradigms enrich our understanding of OCD pathophysiology, suggesting new biomarkers and treatment targets that integrate emotional regulation, temperament, and resilience constructs.

This research marks a significant stride towards a more holistic appreciation of OCD’s complexity. By elucidating how dominant depressive temperament and resilience interweave to influence disorder trajectory, it sets the stage for future longitudinal and interventional studies designed to harness these insights for improved patient outcomes.

As mental health fields evolve with increasing emphasis on biopsychosocial models, such integrative analyses underline the necessity of precision psychometrics and personalized intervention designs. The implications extend beyond OCD, offering a scaffold for examining affective temperament and resilience across a spectrum of psychiatric disorders.

In sum, the intricate tapestry unveiled by this study impresses upon clinicians and researchers alike the imperative to recognize and therapeutically address the nuanced temperament-based variations in OCD. Efforts to enhance psychological resilience, especially in vulnerable temperamental profiles, promise a valuable frontier in mitigating the burden of obsessive-compulsive disorder.

Subject of Research: The interplay between dominant depressive temperament, psychological resilience, and symptom severity in obsessive-compulsive disorder.

Article Title: Dominant depressive temperament and psychological resilience in obsessive-compulsive disorder.

Article References:
Demirkan, A.K., Aydin Sunbul, E., Cengiz Cavusoglu, E. et al. Dominant depressive temperament and psychological resilience in obsessive-compulsive disorder. BMC Psychiatry (2025). https://doi.org/10.1186/s12888-025-07618-1

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12888-025-07618-1

This 16-week, randomized, double-blind, placebo-controlled trial enrolled 60 patients diagnosed with OCD. Participants were assigned to two groups: one receiving escitalopram paired with a placebo, and the other receiving escitalopram combined with memantine. The study meticulously measured two primary outcomes: the severity of OCD symptoms, using the well-validated Yale-Brown Obsessive-Compulsive Scale (Y-BOCS), and executive function capabilities assessed through the Barkley Deficits in Executive Functioning Scale (BDEFS).

OCD’s pathology involves more than just compulsions—it is also closely tied to deficits in executive function, the cognitive processes that enable goal-directed behavior, time management, and flexible problem solving. These deficits contribute to the persistence of OCD symptoms and present a significant obstacle to patient recovery. The hypothesis that memantine, an NMDA receptor antagonist, might enhance executive functioning by modulating glutamatergic neurotransmission offers a promising therapeutic avenue.

Throughout the trial, both groups exhibited significant reductions in OCD symptom severity. The placebo group showed a decrease in Y-BOCS scores from an average of 32.83 at baseline to 5.30 after treatment, while the memantine group decreased from 31.60 to 5.20. Statistically, the difference in OCD symptom reduction between the two groups was not significant, suggesting that memantine did not appreciably augment escitalopram’s efficacy in directly alleviating OCD symptoms.

However, when focusing on executive function, a more nuanced picture emerged. Memantine’s impact was most notable in the domain of time management, where patients in the combination treatment group outperformed those receiving placebo. This finding highlights a selective cognitive benefit that could translate into improved daily functioning and quality of life for patients, despite equivocal effects on core OCD symptoms. Other executive domains measured did not demonstrate significant differences.

Safety and tolerability were critical components of the study. Weekly monitoring for adverse effects revealed a generally mild side effect profile for both treatment arms. Gastrointestinal symptoms appeared slightly more frequently in the memantine group but did not reach statistical significance. This suggests the combination therapy remains a viable option without markedly increasing treatment-related risks.

These findings contribute to a growing body of literature on the neuropharmacological mechanisms underlying OCD and the importance of addressing cognitive deficits alongside symptom control. Memantine’s role as an NMDA receptor antagonist sheds light on glutamatergic dysregulation in OCD, a system distinct from the serotonin pathways targeted by SSRIs. The study advocates for future research to investigate whether long-term administration or higher doses might produce more pronounced clinical benefits.

Moreover, this trial underscores the complexity of treating OCD, a disorder with multifaceted neurocognitive components that may require multi-pronged pharmacological strategies. By targeting executive functions such as time management, interventions can potentially foster better adherence to therapeutic regimens and improve quality of life, even if symptom remission remains partial.

The randomized, double-blind design of this clinical trial strengthens its conclusions by eliminating bias and maximizing the validity of the findings. The sample size, although moderate, was sufficient to reveal statistically significant improvements within groups and trends suggestive of memantine’s cognitive benefits. Nevertheless, larger trials with extended follow-up periods are warranted to confirm these preliminary observations.

In the evolving landscape of psychiatric treatment, augmenting SSRIs with novel agents like memantine offers hope for patients who remain refractory to standard therapies. These innovations emphasize personalized medicine approaches, tailoring interventions not only to symptom severity but also to accompanying cognitive dysfunctions.

Overall, the study from Namazi Hospital and Ibn Sina Polyclinic in Shiraz represents a meaningful step forward in refining OCD management. While memantine did not dramatically shift OCD symptom outcomes compared to placebo, its positive effects on executive function, particularly time management, invite further exploration into how cognitive enhancers can complement traditional antidepressants.

As psychiatric research continues to dissect the biological substrates of OCD, targeting glutamatergic systems alongside serotonergic pathways may unlock new therapeutic potentials. This trial highlights the necessity of integrating symptom-focused and cognition-oriented treatments to achieve holistic patient recovery.

Memantine’s pharmacological profile, well-established in the context of neurodegenerative disorders like Alzheimer’s disease, positions it uniquely for repurposing in psychiatric illnesses marked by cognitive disturbances. Future investigations may refine dosing protocols or combine memantine with behavioral therapies to maximize clinical gains.

In conclusion, this rigorous clinical trial confirms escitalopram’s robust efficacy in reducing OCD symptoms and introduces memantine’s potential utility in selectively enhancing executive function. This dual therapeutic approach signals a paradigm shift toward addressing not only obsessive-compulsive behaviors but also the executive dysfunctions that can perpetuate the disorder.

Subject of Research: The clinical efficacy of memantine augmentation of escitalopram in improving executive function among patients with obsessive-compulsive disorder (OCD).

Article Title: Memantine augmentation of escitalopram in treatment of executive function among patients with obsessive-compulsive disorder (OCD): a double-blind placebo-controlled randomized clinical trial

Article References:
Mirzazadeh, H., Ghaeminia, Y., Mohamad Niaei, A. et al. Memantine augmentation of escitalopram in treatment of executive function among patients with obsessive-compulsive disorder (OCD): a double-blind placebo-controlled randomized clinical trial. BMC Psychiatry 25, 561 (2025). https://doi.org/10.1186/s12888-025-06856-7

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12888-025-06856-7